Results 91 to 100 of about 675 (153)

Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art. [PDF]

Int J Mol Sci, 2023
Diotallevi F, Gioacchini H, De Simoni E, Marani A, Candelora M, Paolinelli M, Molinelli E, Offidani A, Simonetti O.   +8 more
europepmc   +1 more source

THE COST EFFECTIVENESS OF AFAMELANOTIDE FOR THE TREATMENT OF ERYTHROPOIETIC PROTOPORHYRIA [PDF]

Value in Health, 2016
J.C. Thompson, S. Mealing, D. Vetrini, P. Wolgen   +3 more
openaire   +1 more source

Changes in Oral Mucosa Associated with Melanotan II Injections: A Case Report. [PDF]

Life (Basel)
Bonchev A.
europepmc   +1 more source

ACTH: The forgotten therapy [PDF]

, 2018
Montero-Melendez, T
core   +1 more source

Melanocortin 1 Receptor (MC1R): Pharmacological and Therapeutic Aspects. [PDF]

Int J Mol Sci, 2023
Mun Y, Kim W, Shin D.
europepmc   +1 more source

Acute Protoporphyric Hepatopathy as the Initial Presentation of Erythropoietic Protoporphyria in Adulthood. [PDF]

ACG Case Rep J
Alsaleh T, Mohammed A, Karnam M, Roman T.   +3 more
europepmc   +1 more source

Acquired erythropoietic protoporphyria secondary to myelodysplastic syndrome: from mythology to oncologyAcquired Erythropoietic Protoporphyria Secondary to Myelodysplastic Syndrome: From Mythology to Oncology. [PDF]

Acta Derm Venereol
Urosevic-Maiwald M, Kamarachev J, Renner C, Minder AE.   +3 more
europepmc   +1 more source

Etiopathogenesis and Emerging Methods for Treatment of Vitiligo. [PDF]

Int J Mol Sci, 2023
Iwanowski T, Kołkowski K, Nowicki RJ, Sokołowska-Wojdyło M.   +3 more
europepmc   +1 more source

Pathogenesis and clinical management of liver damage in porphyrias: Mechanisms and therapeutic approaches. [PDF]

World J Hepatol
Zeng T, Huang SY, Chen JN, Pang JH, Chong YT, Li XH.   +5 more
europepmc   +1 more source

Pseudoleucoderma After Injections of Afamelanotide in a Patient with Atopic Dermatitis

Acta Dermato Venereologica, 2011
W Bartenwerffer, G Siebenhaar, N Hunzelmann   +2 more
openaire   +2 more sources